Pulmonary Drug Delivery Devices Market By Technology (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers), By Application (Asthma, Copd, Cystic Fibrosis, Diabetes) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

The report titled “Pulmonary Drug Delivery Devices Market- Growth, Future Prospects, and Competitive Analysis, 2017 – 2025” offers strategic insights into the overall pulmonary drug delivery devices market along with the market size and estimates for the duration 2015 to 2025. The said research study covers in-depth analysis of multiple market segments based on type of technology, application, and different geographies. Pulmonary drug delivery devices have been used for decades to deliver drugs for treatment of respiratory diseases. Pulmonary drug delivery pathway is considered as most efficient mode of drug delivery in respiratory diseases because lungs provide a huge surface area of alveoli with vast capillary network which provides an excellent absorbing surface for administration of drugs. Over the decade, rapid onset of action and higher efficiency was observed as the key driving factor for pulmonary delivery systems and also symptomatic relief in treatment of asthma and chronic obstructive pulmonary disease (COPD). Developments in device technology have also led to the development of more proficient delivery systems capable of providing large doses and micro particles into the lung.

For the purpose of this study, the global pulmonary drug delivery devices market is segmented on the basis of technology type into dry powder inhalers, metered dose inhalers, and nebulizers. Furthermore, dry powder inhalers are sub segmented into unit-dose devices and multi-dose devices. Metered dose inhalers are of two types manually actuated pressurized inhalers, and breath actuated pressurized inhaler. Nebulizers comprises jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

The global pulmonary drug delivery devices market is also segmented on the basis of type of applications such as asthma, COPD, cystic fibrosis, diabetes, and others (allergic rhinitis, tuberculosis, among others). Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

The geographical segmentation of pulmonary drug delivery devices market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. Market size and forecast for these segments during 2015 to 2025 and their CAGRs for the period 2017 to 2025 are provided in this report.

The pulmonary drug delivery devices market is observed as the most diversified and competitive market comprising large number of players.  The market is dominated by several players, depending on their major competencies. The key players in this market are GlaxoSmithKline, Boehringer Ingelheim GmbH, 3M, AstraZeneca plc, Merck & Co., Inc., Novartis AG, Omron Corporation and Sunovion Pharmaceuticals Inc. among others.

Pulmonary Drug Delivery Devices Market

For the purpose of this study, the global pulmonary drug delivery devices market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

In base year 2016, North America accounted for the largest market share in year 2016 due to key driving factors such as rising prevalence of asthma and COPD, high public awareness related to early diagnosis and treatment for respiratory disorders, developed healthcare infrastructure, and high accessibility to products with advanced technology. According to Centers for Disease Control and Prevention (CDC), in year 2015 number of adults had asthma were 18.4 million of which 6.2 million were children. During forecast period 2017 – 2025, Asia Pacific was observed as the fastest growing region due to key drivers such as rising prevalence of asthma and COPD, increasing air pollution due to rapid industrial growth, and high public awareness related to respiratory disease diagnosis. According to a report published by United Nations (UN), globally around seven million people a year die prematurely due to indoor and outdoor pollution with about 70 per cent of those deaths in the Asia Pacific.

Pulmonary Drug Delivery Devices Market

Choose License Type
Published Date:  Jul 2017
Category:  Medical Devices
Report ID:   58581
Report Format:   PDF
Pages:   120
Rating:    4.3 (50)
Connect With Us
+1-408-641-3282
24/7 Research Support